Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

omid

omid is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 18
Pipeline programs 15
News articles 0
Drug details — omid
Class
—
Route
—
Patents
18
Programs
15
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

omid is an FDA-listed pharmaceutical active ingredient.

Key facts

INN omid

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. CC-220-MM-002 Phase 3 · Celgene · Relapsed or Refractory Multiple Myeloma (RRMM)
  2. Nicotinomide Phase 3 · United Therapeutics Europe · Glaucoma, Open-Angle
  3. glutamine combined with thalidomide Phase 3 · Chinese Academy of · Mucositis Oral
  4. CC-220-MM-001 Phase 2 · Celgene · Multiple Myeloma
  5. CC-99282-NHL-001 Phase 2 · Celgene · Follicular B-cell non-Hodgkin's lymphoma, Primary central ne
  6. CO43923 Phase 2 · HOFFMANN-LA ROCHE · Multiple Myeloma (MM)
  7. Ezutromid Phase 2 · Summit Therapeutics · Duchenne Muscular Dystrophy
  8. M24-555 Phase 2 · AbbVie Deutschland GmbH · Multiple Myeloma

Related patents

Browse patents

  1. US 12421220

    Bicyclic-substituted glutarimide cereblon binders

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12371442

    Isoindolinone and indazole compounds for the degradation of EGFR

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12227504

    Spirocyclic compounds

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12180225

    N/O-linked degrons and degronimers for protein degradation

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12076405

    Heterocyclic degronimers for target protein degradation

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12048747

    Substituted piperidine Degronimers for Target Protein degradation

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12048748

    Spirocyclic degronimers for target protein degradation

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11992531

    C3-carbon linked glutarimide degronimers for target protein degradation

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11753397

    Cereblon binders for the degradation of ikaros

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11673902

    Isoindolinone and indazole compounds for the degradation of EGFR

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11623929

    Spirocyclic compounds

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11584748

    Spirocyclic compounds

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11459335

    N/O-linked Degrons and Degronimers for protein degradation

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11185592

    Spirocyclic degronimers for target protein degradation

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10905768

    Heterocyclic degronimers for target protein degradation

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10849982

    C3-carbon linked glutarimide degronimers for target protein degradation

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10660968

    Spirocyclic degronimers for target protein degradation

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10646575

    Heterocyclic degronimers for target protein degradation

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is omid?

omid is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.